Fig. 8: Patient mutations uniquely identified by RNA-SM analysis.
From: Pan-cancer discovery of somatic mutations from RNA sequencing data
a Number of patients carrying specific gene mutations as identified by RNA-SM analysis exclusively. Top 15 genes with most mutations are displayed in the graph. Additionally, for each gene, the distribution of patients across cancer types is also presented. b–d KRAS mutations, uniquely identified by RNA-SM analysis, were presented as an example. b Composition of KRAS mutations among cancer patients. c Kaplan–Meier survival analysis to evaluate the prognostic significance of KRAS mutations. Patients with wild-type KRAS were included as a control group. d Selected MSigDB hallmark pathways associated with KRAS mutations. Enrichment scores calculated by GSVA were presented.
